Bristol-Myers Squibb (BMY) is being reclassified across key Russell indexes, exiting several growth benchmarks and entering the Russell 1000 Defensive and Russell 1000 Value Defensive Indexes, a shift that can influence passive fund positioning.

At a share price of US$57.62, Bristol-Myers Squibb has a year to date share price return of 7.78%, while its 1 year total shareholder return of 27.34% contrasts with a 6.66% decline over 90 days. This suggests that recent momentum has cooled following a stronger run.

If you are reviewing how index shifts affect your portfolio mix, it may also be worth scanning other healthcare ideas through our screener of 40 healthcare AI stocks

With Bristol-Myers Squibb now firmly grouped as a value and defensive stock, trading on a forward P/E of 9.1 and at a discount to some analyst targets, the key question is whether this is genuine undervaluation or if the market already reflects future growth.

Most Popular Narrative: 8.5% Undervalued

The most followed narrative currently pegs Bristol-Myers Squibb’s fair value at $62.96, a premium to the $57.62 last close, setting up a valuation gap tied closely to pipeline execution and cash generation assumptions.

Robust late-stage pipeline and ongoing life-cycle management for major brands, along with strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of potential future regulatory approvals and label expansions. This opens additional indications and may help to offset upcoming patent expiries, which is described as supporting top-line and earnings growth in this narrative.

The fair value in this narrative is based on a detailed earnings path, shifting margins and a richer future P/E multiple. Curious which revenue and profit assumptions have to line up to support that outcome? The full narrative explains how falling headline revenue forecasts are presented alongside higher earnings expectations and a premium valuation multiple.

Result: Fair Value of $62.96 (UNDERVALUED)

However, that upside case for Bristol-Myers Squibb also hinges on managing patent cliffs for key drugs like Eliquis and Opdivo, and on drug pricing pressure not biting harder than expected.

Next Steps

Given the mix of optimism and caution around Bristol-Myers Squibb, this is a good time to review the numbers yourself and decide what really matters for your thesis. Then weigh both the upside drivers and flagged concerns by checking the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Bristol-Myers Squibb?

If Bristol-Myers Squibb sharpened your focus on valuation and risk, do not stop here. Broaden your watchlist so you are not relying on a single story.

• Tap into potential mispricings by reviewing companies flagged in our list of 43 high quality undervalued stocks before the crowd fully catches on.
• Strengthen your portfolio’s staying power by scanning stocks featured in the solid balance sheet and fundamentals stocks screener (48 results) that prioritise balance sheet resilience.
• Hunt for lesser known opportunities by reviewing companies highlighted in the screener containing 19 high quality undiscovered gems that may not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.